
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE)--May 16, 2025--
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing research for patients with this disease.
Merck will present pooled data from participants who have completed the PULSAR, SPECTRA, or STELLAR studies and have continued in the ongoing open-label extension study, SOTERIA, evaluating the long-term safety, tolerability and efficacy of WINREVAIR™ (sotatercept-csrk) when added to background therapy for the treatment of PAH. These results represent the largest analysis of WINREVAIR to date.
'The results from this pooled analysis add to the growing body of evidence for WINREVAIR,' said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. 'We remain confident in the long-term potential for WINREVAIR for patients with PAH and look forward to sharing findings as we continue to evaluate WINREVAIR.'
Merck will also present an overall survival analysis for WINREVAIR leveraging data from the pivotal Phase 3 study, STELLAR, and interim data from participants who have continued in the ongoing open-label SOTERIA study, as well as additional outcomes research on the burden and impact of PAH in various patient populations.
Details on Merck abstracts at ATS:
About WINREVAIR ™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
Selected Safety Information for WINREVAIR in the U.S.
WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.
WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.
The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%).
Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.
About PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).
Please see Prescribing Information for WINREVAIR (sotatercept-csrk) athttp://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf, Patient Information for WINREVAIR athttp://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ppi.pdf, and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) athttps://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515033520/en/
CONTACT: Media Contacts:
Julie Cunningham
(617) 519-6264
Courtney Ronaldo
(908) 442-5695
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: SCIENCE CARDIOLOGY DATA ANALYTICS RESEARCH GENERAL HEALTH HEALTH PROFESSIONAL SERVICES CLINICAL TRIALS
SOURCE: Merck & Co., Inc.
Copyright Business Wire 2025.
PUB: 05/16/2025 06:45 AM/DISC: 05/16/2025 06:46 AM
http://www.businesswire.com/news/home/20250515033520/en
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
16 minutes ago
- Wall Street Journal
Voyager Technologies Rises in Debut, Signaling Improving IPO Market
Shares of space and defense technology company Voyager Technologies surged in their New York Stock Exchange debut Wednesday, another sign of an improving market for initial public offerings. The stock ended the regular session at $56.48 and was up 6% after hours to $60.15.


Skift
18 minutes ago
- Skift
Planners Fear Immigration Crackdowns Will Make Hotel Labor Shortages Worse: Exclusive Survey
The hospitality industry has struggled with a labor shortage since the Covid pandemic. Now, immigration enforcement and an anti-immigrant sentiment are adding a new layer of complexity. An exclusive Skift Meetings survey of U.S. planners shows that they expect to grapple with the effects of Trump-era immigration policies on their events, with growing concern about hotel staffing across the board. More than two-thirds of respondents (72%) said they expect hotel staffing to be affected in 2025–2026 because of immigration policies. Only 13% foresaw no impact. 'Hotel staffing never fully bounced back after the pandemic. We're still experiencing some gaps in service in certain markets and at certain properties,' said Kyle Jordan, director of meetings at the Institute for Operations Research and Management Sciences (INFORMS). Staffing issues are being felt at more than hotels. 'Challenges extend to other key partners like AV providers and vendors that support our meetings,' said Jordan. 'While it's hard to predict the full impact, I would expect that deportation activity could further strain staffing in some destinations.' Concerns stem not just from general staffing shortages but also the effect of revived immigration enforcement policies. 'The main issue is that for many workers in hotels, while they may be legal immigrants, the feeling toward immigrants in general has turned toxic,' said Mark Phillips, CEO of LamontCo. 'No one wants to live and work in such an environment or put families through it, so over time we will see less available even legal immigrant workforces. It already appears to be happening in several cities.' ICE Raids and Protests Exacerbate Immigration Issues In Los Angeles, several days of protests followed large-scale immigration raids by ICE. Protests have spread to other U.S. cities, including Atlanta, Chicago, Washington, D.C, and New York City. a'The hospitality industry relies heavily on immigrant labor especially in back-of-house roles like housekeeping, food and beverage service, and maintenance. Stricter immigration enforcement, increased deportations, and general anti-immigration rhetoric have created fear and uncertainty among these workers, not to mention ICE raids, and I-9 audits. This leads some to leave the industry or self-deport, reducing the labor pool, making it even harder for hotels to fill critical positions,' said Robert Kraus, founder of Small Conferences. Kraus added that there are concerns about the future of the H-2B visa program and similar initiatives. 'There's also a worry that H-2B visas and other temporary worker programs will be curtailed plus general apprehension on potential workers to risk coming to the U.S. just to be told they can't enter or later be sent home only after a short amount of time. This could easily limit the number of foreign workers applying, which is critical for meeting seasonal demands of resorts and other hospitality businesses.' Labor shortages have already disrupted event logistics.'In several cases, my groups suffered through multi-hour lunch services because the hotel restaurant kitchen could not keep up with demand,' he said. Legal Compliance Doesn't Eliminate Anxiety Michael Dominguez, president and CEO of ALHI, argues that deportation is not necessarily a direct impact to hotel staffing. 'It has been required by law for any employee to complete an I-9 form, which verifies legal status and requires documentation,' said Dominguez. 'Any company or hotel not doing that is in violation of Section 274A of the Immigration and Nationality Act of 1986. Everyone working in a hotel needs documentation, or they are breaking the law.' Still, legal status does not erase worker anxiety, said Melanie Nathan, human rights advocate and executive director of the African Human Rights Coalition. 'I know people who are perfectly legal and who have filled in those I-9's who are too scared to go to work. They are standing back to try and ride out what they feel like is a storm. Some fear they might get picked up in workplaces where there are likely to be raids.' Guest Services and Sales Take a Hit The staffing crunch is also affecting guest experience and hotel revenue. 'Daily housekeeping is no longer a given. There are hotels where it is now every other day or on request,' said Akshar Patel, VP of corporate strategy and development at eShow Event Management Solutions and a hospitality expert. Beyond guest services, the staffing crunch is slowing business development efforts. 'A staffing shortage on the sales side is delaying RFPs,' said Patel. Andrea Milrad Heilweil, VP of sales and marketing at The Hutton Group, agrees. 'I have found that since Covid I have to be much more proactive with follow-up. Between people furloughed, laid off, or leaving the industry altogether, RFP responses, requests for contracts, setting up site visits, and general communication have been delayed.'


CBS News
18 minutes ago
- CBS News
Dr. Macquline King named interim Chicago Public Schools CEO by Board of Education
The Chicago Board of Education selected City Hall employee Dr. Macquline King to be the interim CEO of Chicago Public Schools. The board voted on her appointment Wednesday. King will replace outgoing CPS CEO Pedro Martinez, who the board voted out in December 2024 amid an ongoing battle with Mayor Brandon Johnson over funding for the city's public school system. In September 2024, Martinez said he refused a request from Johnson to resign from his post after he declined the mayor's request to take out a $300 million high-interest short-term loan to pay for the costs of the proposed new Chicago teachers' contract and pension costs previously covered by the city. The entire previous school board resigned in October after being pressured by the mayor to fire Martinez. Johnson chose a new school board within days. In November, 10 new members of the school board were elected by the people of Chicago. CPS has been searching for a new permanent head for the district ever since, and a new permanent head has yet to be selected. So far, Dr. King is only the interim CPS CEO. She currently serves as the senior director of educational policy at City Hall. CPS faces a deficit of over half a billion dollars for the 2026 fiscal year, which begins July 1.